Our in vivo study indicated that dyslipidemia not only elevated the level of ApoC3 in the apolipoprotein component of LDL, but that it also induced vascular endothelial senescence and enlarged the atherosclerotic lesion size. Here, APOC3 is linked to metabolic syndrome.